Browse diseases

…rtant prognostic factors is the clonal relationship between the CLL/SLL and DLBCL tumours. Cases of DLBCL-type Richter transformation t…

…usions Spatial organization of M+2+6- cells is a novel facet in DLBCL. Dispersed patterns create immunosuppressive microenvironments …

…cted OS (HR 1.8).These factors underscore the dual challenge in DLBCL: maximising therapeutic delivery while mitigating inherent dise…

…= 53, 76%), acute lymphoblastic leukaemia (ALL, n = 6, 9%), and multiple myeloma (MM, n = 6, 9%). CAR-T products: axicabtagene ciloleucel (n = 3…

…Primary ovarian lymphoma is a rare malignancy, representing <1% of ovarian neoplasms and…

…Background Diffuse Large B-Cell Lymphoma (DLBCL), the most common non-Hodgkin lymphoma (>18,000 US cases…

…as 23.3 for ccRCC (kidney), 1.9 for DLBCL (spleen), and 3.6 for MESO (lung). In comparative analyses, CD70 expression in ccRCC was s…

…9) CAR-T cells as well as anti-CD20 bispecific antibodies, with lymphoma cells resulting in CD19 and CD20 antigen loss.Conclusions This …

…ave significantly improved treatment outcomes for patients with non-Hodgkin lymphoma. However, patients with aggressive disease experience high refr…

…Diffuse large B cell lymphoma (DLBCL) is a prevalent subtype of non-Hodgkins lymphoma and can occasionally present as a rare and aggressive testicula…

…use large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin’s lymphoma. Although standard immunochemotherapy is available, 30%–40% of …

…B-cell neoplasms, most notably lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinaemia (WM) (>90%), IgM monoclonal gammopathy of undetermined signific…